sitagliptin + metformin

Sitagliptin + metformin is a fixed-dose oral combination medication used to manage type 2 diabetes mellitus. It combines two antihyperglycemic agents with complementary mechanisms of action. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases levels of incretin hormones, stimulating the pancreas to release more insulin in response to meals and reducing hepatic glucose production by lowering glucagon levels. Metformin is a biguanide that decreases hepatic glucose production, reduces intestinal absorption of glucose, and improves insulin sensitivity in peripheral tissues. The combination provides improved glycemic control compared to either agent alone and is indicated as an adjunct to diet and exercise for adults with type 2 diabetes[1][2][3][6][8].

Brand names

JanumetJanumet XRZituvimetZituvimet XRSitagliptin/Metformin hydrochloride Accord

Other names

sitagliptin and metformin